SCHEMBL757790

SCHEMBL757790

Cc1ccccc1COC(=O)N1CCCCC1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.44
ITGB1 P05556 1/20 0.43
ITGA4 P13612 1/20 0.43
ALDH1A1 P00352 3/20 0.40
F13A1 P00488 1/20 0.40
TGM2 P21980 1/20 0.40
TGM1 P22735 1/20 0.40
GAA P10253 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
PGGT1B P53609 1/20 0.39
LMNA P02545 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
MAOB P27338 1/20 0.39
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL520364 0.81 NPC1 (0.58) ALDH1A1GAAMEN1KMT2A
SCHEMBL31350203 0.80 NPC1 (0.57) GAAMEN1KMT2A
SCHEMBL8327710 0.80 P2RX4 (0.45) GRIN2BMEN1KMT2AKDM4EMAPT
SCHEMBL1336227 0.78 LMNA (0.48) ALDH1A1MEN1KMT2APOLBLMNA
SCHEMBL23850757 0.77 GRIN2B (0.58) GRIN2BALDH1A1F13A1TGM2TGM1
SCHEMBL8325442 0.77 POLB (0.48) GRIN2BALDH1A1MEN1KMT2APOLB
SCHEMBL9619391 0.77 LMNA (0.47) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL520065 0.76 NPC1 (0.59) ALDH1A1GAAMEN1KMT2ALMNA
SCHEMBL15465892 0.74 KMT2A (0.43) KMT2APOLB
SCHEMBL7326923 0.73 NPC1 (0.50) GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399473-B2 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-03-19 US disclosed
EP-2073635-B1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-03-21 EP disclosed
US-20100029701-A1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-02-04 US disclosed
EP-2073635-A1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2009-07-01 EP disclosed
WO-2008045250-A1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029701-A1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BACE1, BACE2, APP GRIN2B 1441/4885ITGB1 3131/4885ITGA4 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.